Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
4(36%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
9%
Ph phase_2
5
45%
Ph phase_4
1
9%
Ph phase_1
4
36%

Phase Distribution

4

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
1(9.1%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(7)
Completed(3)
Terminated(1)

Detailed Status

Recruiting4
Not yet recruiting3
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (36.4%)
Phase 25 (45.5%)
Phase 31 (9.1%)
Phase 41 (9.1%)

Trials by Status

recruiting436%
withdrawn19%
not_yet_recruiting327%
completed327%

Recent Activity

4 active trials
Showing 5 of 11
not_yet_recruitingphase_4

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

NCT07014540
recruitingphase_1

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

NCT06782685
recruitingphase_2

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

NCT06184698
recruitingphase_2

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

NCT06341296
not_yet_recruitingphase_3

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

NCT06501664
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07014540Phase 4

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not Yet Recruiting
NCT06782685Phase 1

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

Recruiting
NCT06184698Phase 2

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Recruiting
NCT06341296Phase 2

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

Recruiting
NCT06501664Phase 3

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Not Yet Recruiting
NCT06225622Phase 1

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting
NCT06210360Phase 2

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not Yet Recruiting
NCT03162510Phase 1

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

Completed
NCT02884128Phase 1

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

Completed
NCT01889680Phase 2

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

Withdrawn
NCT02090153Phase 2

Study of S-1 Plus LV for Advanced Gastric Cancer

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11